Skip to main content
Content Starts Here GSA Federal Advisory Committee Act (FACA) Database Skip to main content

Committee Detail

Note: An Annual Comprehensive Review, as required by §7 of the Federal Advisory Committee Act, is conducted each year on committee data entered for the previous fiscal year (referred to as the reporting year). The data for the reporting year is not considered verified until this review is complete and the data is moved to history for an agency/department. See the Data From Previous Years section at the bottom of this page for the committee’s historical, verified data.

HHS - 1009 - Psychopharmacologic Drugs Advisory Committee - Authorized by Law


Committee NamePsychopharmacologic Drugs Advisory CommitteeAgency NameDepartment of Health and Human Services
Fiscal Year2020Committee Number1009
Original Establishment Date11/28/1990Committee StatusChartered
Actual Termination Date Committee URL
New Committee This FYNoPresidential Appointments*No
Terminated This FYNoMax Number of Members*10
Current Charter Date6/4/2020Designated Fed Officer Position Title*Designated Federal Officer
Date Of Renewal Charter6/4/2022Designated Federal Officer Prefix
Projected Termination Date Designated Federal Officer First Name*Yvette
Exempt From Renewal*NoDesignated Federal Officer Middle Name
Specific Termination AuthorityDesignated Federal Officer Last Name*Waples
Establishment Authority*Authorized by LawDesignated Federal Officer SuffixPharmD
Specific Establishment Authority*21 U.S.C. 394Designated Federal Officer Phone*(301) 796-9001
Effective Date Of Authority*11/28/1990Designated Federal Officer Fax*301-847-8533
Exempt From EO 13875 Discretionary CmteExempt: Consumer Product Safety CmteDesignated Federal Officer Email*
Committee Type*Continuing
Committee Function*Scientific Technical Program Advisory Board


Agency Recommendation*Continue
Legislation to Terminate RequiredNot Applicable
Legislation StatusNot Applicable
How does cmte accomplish its purpose?*The Committee reviews and evaluates available data concerning the safety and effectiveness of marketed and investgational human drug products for use in the practice of psychiatry and other related fields and makes appropriate recommendations to the Commissioner of Food and Drugs.
How is membership balanced?*Members are experts in psychopharmacology, psychiatry, and epidemiology or statistics who are qualified by training and experience to evaluate scientific data. The committee has one technically qualified member identified with consumer interests. In addition to the voting members, the Committee includes one non-voting member who is identified with industry interests.
How frequent & relevant are cmte mtgs?*The Committee did not meet in FY-20.
It is expected that the Committee will meet one to three times in FY-21.
Why advice can't be obtained elsewhere?*Members of the Committee are drawn from academia, research, and/or clinical practice. Their advice and input lends credibility to regulatory decisions, which helps those decisions stand up to intense public scrutiny. The alternate means of obtaining this advice would involve the recruitment of large numbers of scientist on a full-time basis at a maximum rate of compensation.
Why close or partially close meetings?The Committee held no closed meetings during FY-20.
Recommendation RemarksAlthough this Committee did not meet in FY-20, considerable time was devoted to appointing members, maintaining associated records for these activities, and streamlining paper processes within FDA. In addition, time was spent in the routine care and maintenance of the Committee: the development of a financial report for this website; updating the roster and number of vacancies on our website; completing the annual ethics report; reviewing financial disclosures of current members and providing ethics training.


Outcome Improvement To Health Or Safety*YesAction Reorganize Priorities*Yes
Outcome Trust In GovernmentYesAction Reallocate ResourcesYes
Outcome Major Policy ChangesYesAction Issued New RegulationsYes
Outcome Advance In Scientific ResearchYesAction Proposed LegislationYes
Outcome Effective Grant MakingNoAction Approved Grants Or Other PaymentsNo
Outcome Improved Service DeliveryNoAction OtherYes
Outcome Increased Customer SatisfactionYesAction CommentRecommendation: FDA approves or chooses not to approve an investigational new medical product.
Outcome Implement Laws/Reg RequirementsYesGrants Review*No
Outcome OtherNoNumber Of Grants Reviewed0
Outcome CommentNANumber Of Grants Recommended0
Cost Savings*Unable to DetermineDollar Value Of Grants Recommended$0.00
Cost Savings CommentThe utilization of the Psychopharmacologic Drugs Advisory Committee enabled the Agency to obtain required and frequently scarce professional services from medical and scientific experts not otherwise available to the Agency; an to obtain the services of these experts only on an as needed basis rather than on a full time basis. The service of the Committee resulted in advice for the improvement of the public health, for which it is difficult to assign a financial value.Grants Review CommentNA
Number Of Recommendations*32Access Contact Designated Fed. Officer*Yes
Number Of Recommendations CommentThe Committee made 32 recommendations from FY-03 through FY-20.Access Agency WebsiteYes
% of Recs Fully Implemented*84.00%Access Committee WebsiteYes
% of Recs Fully Implemented CommentThe function of an advisory committee is purely advisory in nature. Although the FDA most often accepts the recommendations from its committees, the advice is purely advisory in nature, therefore, the Agency has the option of not implementing the advice. This number represents an approximation of the percentage of recommendations that the agency has fully implemented or plans to fully implement.Access GSA FACA WebsiteYes
% of Recs Partially Implemented*10.00%Access PublicationsYes
% of Recs Partially Implemented CommentThe function of an advisory committee is purely advisory in nature. Although the FDA most often accepts the recommendations from its committees, the advice is purely advisory in nature, and therefore, the Agency has the option of not implementing the advice.Access OtherNo
Agency Feedback*YesAccess CommentN/A
Agency Feedback Comment*When appropriate, information is made available to the public. Actions related to guidance documents or other general matters issues are available publicly when implemented.Narrative Description*FDA’s strategic priorities in responding to the public health challenges of the 21st century are to advance regulatory science and innovation; strengthen the safety and integrity of the global supply chain; strengthen compliance and enforcement activities to support public health; expand efforts to meet the needs of special populations; advance medical countermeasures and emergency preparedness; advance food safety and nutrition; promote public health by advancing the safety and effectiveness of medical products; establish an effective tobacco regulation, prevention, and control program; and manage for organizational excellence and accountability. The Psychopharmacologic Drugs Advisory Committee supports FDA's strategic priorities by reviewing and evaluating data concerning the safety and effectiveness of marketed and investigational human drug products for use in the practice of psychiatry and related fields and makes appropriate recommendations to the Commissioner of Food and Drugs. This supports the development of safe and effective new medical technologies, and advances the status of the Agency as a science-based and science-led regulatory agency, providing global leadership in the protection of public health.
Hide Section - COSTS


Payments to Non-Federal Members*$0.00Est Payments to Non-Fed Members Next FY*$8,800.00
Payments to Federal Members*$0.00Est. Payments to Fed Members Next FY*$2,200.00
Payments to Federal Staff*$180,093.00Estimated Payments to Federal Staff*$182,185.00
Payments to Consultants*$0.00Est. Payments to Consultants Next FY*$4,400.00
Travel Reimb. For Non-Federal Members*$0.00Est Travel Reimb Non-Fed Members nextFY*$12,107.00
Travel Reimb. For Federal Members*$0.00Est Travel Reimb For Fed Members*$4,086.00
Travel Reimb. For Federal Staff*$0.00Est. Travel Reimb to Fed Staff Next FY*$0.00
Travel Reimb. For Consultants*$0.00Est Travel Reimb to Consultants Next FY*$5,112.00
Other Costs$45,023.00Est. Other Costs Next FY*$51,522.00
Total Costs$225,116.00Est. Total Next FY*$270,412.00
Federal Staff Support (FTE)*1.10Est. Fed Staff Support Next FY*1.10
Cost RemarksThe Committee did not meet in FY-20.Est Cost RemarksThese estimates include the costs for two potential advisory committee meetings in FY-2021.
Hide Section - Interest Areas

Interest Areas

Food and Drugs
Food and Drugs
Health Care


To View all the members, meetings and advisory reports for this committee please click here


No Documents Found



Data from Previous Years

ActionCommittee System IDCommittee NameFiscal Year
 COM-036607Psychopharmacologic Drugs Advisory Committee2019
 COM-034811Psychopharmacologic Drugs Advisory Committee2018
 COM-001619Psychopharmacologic Drugs Advisory Committee2017
 COM-002397Psychopharmacologic Drugs Advisory Committee2016
 COM-003761Psychopharmacologic Drugs Advisory Committee2015
 COM-004707Psychopharmacologic Drugs Advisory Committee2014
 COM-005857Psychopharmacologic Drugs Advisory Committee2013
 COM-006612Psychopharmacologic Drugs Advisory Committee2012
 COM-008395Psychopharmacologic Drugs Advisory Committee2011
 COM-008777Psychopharmacologic Drugs Advisory Committee2010
 COM-010366Psychopharmacologic Drugs Advisory Committee2009
 COM-010710Psychopharmacologic Drugs Advisory Committee2008
 COM-012190Psychopharmacologic Drugs Advisory Committee2007
 COM-012860Psychopharmacologic Drugs Advisory Committee2006
 COM-014072Psychopharmacologic Drugs Advisory Committee2005
 COM-014537Psychopharmacologic Drugs Advisory Committee2004
 COM-015723Psychopharmacologic Drugs Advisory Committee2003
 COM-016559Psychopharmacologic Drugs Advisory Committee2002
 COM-017868Psychopharmacologic Drugs Advisory Committee2001
 COM-018377Psychopharmacologic Drugs Advisory Committee2000
 COM-019781Psychopharmacologic Drugs Advisory Committee1999
 COM-020644Psychopharmacologic Drugs Advisory Committee1998
 COM-021424Psychopharmacologic Drugs Advisory Committee1997